Biocon Ltd.'s first-quarter net profit rocketed 72% and India's largest biologics group has forecast a strong full-year performance, insisting its US launch of biosimilar trastuzumab will be “very successful” despite the surprise early market debut of Amgen Inc.’s rival product.
Amgen’s 19 July launch of Kajinti, a biosimilar of Roche’s blockbuster HER2-positive breast cancer drug Herceptin, means Biocon and partner Mylan NV will be deprived of exclusivity benefits in the US when they market their
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?